The efficacy of endocrine tests depends on the choice of tests, the preparation of the patients, the integrity of the specimens, the quality of the measurements, and the validity of the reference data. Close dialogue among the clinicians, the laboratory, and the patients is a key factor for optimal patient care. The characteristics of urine and plasma samples and the advantages and limitations of paired test measurements are presented. The importance of test sequence strategies, provocative or inhibitory procedures, and elimination of drug interferences is illustrated with four cases involving Cushing syndrome, pheochromocytoma, primary aldosteronism, and hypercalcemia. For each of these scenarios, key clinical issues are highlighted, along with discussions of the best test strategies, including which medications are likely to interfere. The importance of targeting laboratory tests to answer well-focused clinical decisions is emphasized. The roles of some time-honored provocative procedures are questioned in light of more sensitive and specific analytic methods. The importance of decision-focused analytical tolerance limits is emphasized by demonstrating the impact of analytic bias on downstream medical resource utilization. User-friendly support systems to facilitate the implementation of test strategies and postanalytic tracking of patient outcomes are presented as essential requirements for quality medical practice.
Consider the hypothetical situation in which laboratory tests are limited (precious resources that are rationed) such that a healthcare provider could use only a controlled number of resource units per definable patient care outcome event. In this perhaps not so hypothetical environment, a clinician would want to ensure that the most appropriate tests are ordered to provide the best chance of answering the key diagnostic and therapeutic questions and that the patient is properly prepared for optimal testing. It would be best to have these tests performed by reliable methods in a laboratory that has well-defined reference information needed for interpreting the test results. It also would be important to understand the specific patient care outcome events that the healthcare system is tracking and to use this information for continuous quality improvement.
This report describes two general concepts that are important in choosing optimal laboratory test strategies: (a) the advantages and limitations of urine and blood measurements and (b) the utility of paired trophic and target hormone measurements. Four endocrine disorders that involve specialized laboratory tests are presented to illustrate potential test strategies. For each of these, a series of questions is posed for investigation before ordering laboratory tests:
(a) What are the key clinical issues? (b) What sequence of tests would be optimal? (c) What drugs should be discontinued before testing? (d) What stabilizing, provocative, or inhibitory procedures should the patient undergo before the specimen collection?
Choice of Specimen
Twenty-four-hour urine specimens are used for many endocrine tests. Urine specimens represent a time average that integrates over the multiple pulsatile spikes of hormone secretion occurring throughout the day. The 24-h urine specimen also has the advantages of better analytic sensitivity for some hormones (1, 2 ) . Urine often contains not only the original hormone, but also key metabolites that may or may not have biologic activity. For some hormones, mainly the free (unbound) component is secreted in the urine (e.g., urinary free cortisol). The drawbacks of urine specimens are the inconvenience and delays of collecting the 24-h specimen. (For some analytes, the first-morning or second-morning urine may be a more convenient alternative.) Another limitation of urine specimens is the uncertainty of the collection completeness. Measurement of urinary creatinine concentrations helps in monitoring collection completeness, especially when it is compared with the muscle mass of the patient. Many urinary hormones are conjugated to carrier proteins before excretion. Therefore, both hepatic function and, to a lesser degree, renal function may alter urinary hormone values. Blood specimens have both the advantage and the limitation of time dependency. Most hormones have substantial biologic variation, including ultradian, diurnal, menstrual, and seasonal variations (3) (4) (5) . Many hormones have short half-lives and are rapidly cleared from the blood. Half-lives are particularly important when the response to a provocative drug, such as the effect of gonadotropin-releasing hormone, is being measured (6 ) .
Simultaneous measurement of trophic and target hormones may help to determine the location of the abnormality. Hyperfunction and hypofunction generally are defined in terms of the target hormone concentrations. Primary hyperfunction means the target gland is autonomously overproducing the stimulatory hormone, whereas secondary hyperfunction means that the trophic gland is overproducing. Similarly, primary hypofunction implies target gland failure, whereas secondary hypofunction implies trophic gland failure. Fig. 1 illustrates how simultaneous target hormone and trophic hormone measurements can be used to classify endocrine disorders.
An example of paired hormone measurements is serum thyrotropin from the pituitary as the trophic hormone with thyroxine and triiodothyronine from the thyroid gland as target hormones. An increased concentration of serum thyrotropin with low thyroxine and triiodothyronine is characteristic of primary hypothyroidism. Another example is corticotropin (ACTH) 1 as the trophic hormone paired with cortisol as the target hormone for Cushing disease (hyperfunction) and Addison disease (hypofunction). A more complex example is growth hormone as the trophic stimulus for the liver production of insulin-like growth factor I, which can cause excess growth (acromegaly or giantism) or the deficient growth of dwarfism.
Patients with hormone resistance may present as potentially confusing inconsistencies between target hormone and trophic hormone concentrations. For example, thyroid hormone resistance may present with increased thyrotropin, with normal or increased thyroid hormone concentrations. On the other hand, pseudohypoparathyroidism may present with increased parathyroid hormone (PTH) concentrations and hypocalcemia. These hormone resistance syndromes or "pseudo" disease states require careful correlation of the clinical presentation of the patient (and family members) with the laboratory test results.
The four endocrine disorders selected for these test strategy paradigms are Cushing syndrome, pheochromocytoma, primary aldosteronism, and hypercalcemia.
Cushing Syndrome
Cushing syndrome is relatively rare, with only ϳ10 cases per 1 million people (7 ) . Therefore, it is important to have a sensitive and specific screening test. Measurement of urinary free cortisol is the recommended screening test (8 ) . However, measurement of urinary free cortisol will not work well as a screening test in a general population with a low prevalence of disease; therefore, it is important to test only patients who have specific clinical signs and symptoms, such as central obesity, facial plethora, proximal muscle weakness, wide purple striae, or unexplained osteoporosis, rather than testing all patients or all patients with nonspecific conditions such as obesity or hypertension. Before testing, clinicians and laboratorians should ascertain that the patient is not using exogenous glucocorticoids, including topical preparations such as hemorrhoid medications, which could contaminate urine collections. Some HPLC methodologies can separate exogenous steroids, but most immunoassay methods cross-react with synthetic steroids. This cross-reactivity can cause substantial interference. Chronic alcohol abuse also causes hypercortisolism, which can mimic Cushing syndrome (9 ) . Clinicians should try to ensure that alcoholic patients refrain from drinking at least 1 month before testing.
Some medical centers recommend the 1-mg overnight dexamethasone suppression test followed by morning plasma cortisol measurement as the preferred screening test for Cushing syndrome. However, this generally does not perform as well as urinary free cortisol (10, 11 (12 ) .
Once a diagnosis of endogenous hypercortisolism has been made (generally with two urinary free cortisol measurements), the next step is to localize the abnormality (13 ) . The paired measurement of ACTH and cortisol determines whether the disease is ACTH-independent or ACTH-dependent. ACTH-independent disease generally implies an adrenal source, which typically can be documented with magnetic resonance imaging. ACTH-dependent and borderline cases require further testing, usually involving ACTH-releasing hormone stimulation and/or dexamethasone suppression with either low-or high-dose protocols (14, 15 ) . The low-dose dexamethasone test consists of baseline measurements followed by administration of nine doses of 0.5 mg of dexamethasone every 6 h and measurements of urinary free cortisol and plasma cortisol during the last 24 h. Failure of cortisol suppression indicates Cushing syndrome. The high-dose dexamethasone test consists of nine doses of 2 mg or 4 mg of dexamethasone every 6 h with follow-up cortisol measurements. Most patients with pituitary-dependent Cushing syndrome will have suppressed cortisol concentrations, whereas patients with adrenal neoplasms or ectopic ACTH syndrome usually have minimal suppression.
If the source of ACTH cannot be localized conclusively, bilateral inferior petrosal sinus sampling may be necessary. This is a complex procedure involving collection of blood from catheters placed into the left and right parts of the inferior petrosal venous system draining the pituitary gland (16, 17 ) . Comparison of ACTH concentrations in these specimens with the ACTH concentration in a concurrently collected peripheral blood sample allows the calculation of flow gradients and better determination of the source of the ACTH. Measurements of ACTH before and after stimulation with ACTH-releasing hormone enhance the diagnostic accuracy. A ratio Ͼ2.0 for the baseline inferior petrosal sinus to the peripheral ACTH concentration or a ratio Ͼ3.0 after administration of ACTHreleasing hormone is consistent with pituitary-dependent Cushing syndrome.
Pheochromocytoma
Catecholamine-secreting tumors are another rare disorder, with ϳ2-8 cases per 1 million people per year (18 ) .
The term "pheochromocytoma" technically refers to catecholamine-producing tumors that arise from the chromaffin cells of the adrenal medulla, but its use here also includes catecholamine-secreting paragangliomas.
The approach to suspected pheochromocytoma depends on the level of clinical suspicion (19 ) . Optimal test reliability is achieved by eliminating interfering medications and timing the specimen collection to be concurrent with the clinical spells. These hypertension-related spells often are associated with headache, palpitations, diaphoresis, pallor, nausea, anxiety, tremor, and epigastric or chest pain (20 ) . A spell usually lasts 10 -60 min and may occur daily or only a few times a year.
Biochemical testing should precede imaging studies. The 24-h urinary excretion rates of catecholamines and their metabolites are the tests of choice (21 ) . If the clinical suspicion is high, screening with a combination of measurements of metanephrines, catecholamines, and vanillylmandelic acid is recommended to expedite the workup. If the clinical suspicion is lower or if time is not an issue, only measurement of metanephrines is recommended for the initial screen, and the catecholamine and vanillylmandelic acid tests are performed if the metanephrines are increased. In either case, measurement of urinary creatinine is recommended to ensure completeness of collection. Patients with pheochromocytomas generally have a twofold increase in epinephrine or norepinephrine excretion rates or an increased metanephrine concentration (22 ) . With current test methodologies, this test strategy is as sensitive as the previously used histamine and glucagon stimulation tests, rendering these stimulation tests obsolete. In the past 20 years at the Mayo Clinic, none of the patients with negative test results for 24-h urinary catecholamine or catecholamine metabolites have had positive results on these provocative tests (21 ) .
Patients with suspected pheochromocytoma often are receiving numerous medications, particularly antihypertensive agents. Labetalol, an antihypertensive medication, interferes with many metanephrine and catecholamine assays; therefore, it should be discontinued 4 -7 days before testing (see Table 1 ). Tricyclic antidepressants also interfere with many of these assays and should be tapered and discontinued ϳ2 weeks before testing. Dopaminerelated drugs also can interfere with these measurements.
Measurement of urinary catecholamines may not be valid in patients with advanced renal disease (23, 24 ) . For such patients plasma catecholamine concentrations may be helpful; however, higher decision levels, such as a threefold increase for norepinephrine and a twofold increase for dopamine, should be used to help identify catecholamine-secreting tumors in hemodialyzed patients.
Special care should be taken when collecting plasma specimens for catecholamine testing. Many patients autonomously activate their fight or flight hormones when blood is collected. The protocol outlined in Fig. 2 is designed to minimize interference in this collection process.
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Primary Aldosteronism
The syndrome of hypertension, hypokalemia, suppressed plasma renin activity, and increased aldosterone excretion is consistent with primary aldosteronism. Although initially considered relatively rare, more cases (0.05-2% of the population) are being diagnosed when the symptoms are evaluated biochemically (25 ) . The diagnosis of this disorder is important because it is a curable form of hypertension. Multiple subtypes of this disorder have been identified, some of which are linked to specific genes (26 ) . Some of these subtypes may have normal potassium concentrations; therefore, normokalemia does not exclude the diagnosis of primary aldosteronism (27, 28 ) .
The best screening tests are the paired measurements of plasma renin activity (PRA) and plasma aldosterone concentration (PAC) (19 ) . When PAC is measured in units of nanograms per deciliter and PRA is measured in units of nanograms per milliliter per hour, a high ratio of PAC to PRA (Ͼ20) is a positive screening test result. The PAC typically is Ͼ200 ng/L (Ͼ20 ng/dL), whereas the PRA typically is low. If PAC and PRA concentrations are increased and the ratio is Յ10, the patient should be investigated for secondary causes of hyperaldosteronism. On the other hand, if both PRA and PAC are depressed, other adrenal and metabolic disorders should be considered (Fig. 3) .
Patients with a positive result of a screening test for primary aldosteronism should undergo confirmation testing. The confirmatory test involves measurement of PAC after 3 days of salt loading with potassium supplementation. Spironolactone and angiotensin-converting enzyme inhibitor medications should be replaced with other drugs before testing. On the third day, a 24-h urine specimen is collected and used to measure aldosterone, sodium, and potassium. Excretion of Ͼ200 mEq of sodium/24 h assures adequate sodium load. Urinary aldosterone excretions Ͼ12 mg/24 h are consistent with hyperaldosteronism.
Hypercalcemia
The differential diagnosis of hypercalcemia depends on the clinical setting (29, 30 ) . Overall, primary hyperparathyroidism and malignancy account for 80 -90% of hypercalcemia cases; however, primary hyperparathyroidism is the cause of ϳ60% of the ambulatory cases and of ϳ25% of the hospitalized cases, whereas malignancy causes ϳ35% of the ambulatory cases and 65% of the hospitalized cases.
A 1990 NIH Consensus Development Conference Panel for the Diagnosis and Management of Asymptomatic Primary Hyperthyroidism recommended two calcium determinations followed by immunoassay of intact PTH as the most efficient way to evaluate these patients (31 ) . They specifically emphasized the importance of proper specimen collection and withdrawal of interfering medications.
The hypercalcemia should be confirmed under conditions of minimal venous occlusion after withdrawal of potentially causal drugs such as thiazide diuretics. A 24-h urinary calcium measurement and excretory urograms often are helpful for characterizing patients with PTHmediated hypercalcemia. Measurement of the ionized calcium concentration may be useful in patients with altered serum albumin concentrations. Most patients with hyperparathyroidism have borderline increased or high normal concentrations of intact PTH. Even high normal PTH values should be considered abnormal because patients with increased calcium values should normally have suppressed PTH concentrations. However, high normal PTH and hypercalcemia may be present in patients with familial hypocalciuric hypercalcemia (32 ) . A low 24-h urinary calcium concentration (Ͻ100 mg/24 h) suggests this disorder, but a normal concentration does not rule out familial hypocalciuric hypercalcemia. Careful family history and lifelong increased calcium values in the patient are valuable clues for identifying familial hypocalciuric hypercalcemia.
Recently, interoperative measurements of PTH have been advocated for assuring effectiveness of parathyroid surgery (33, 34 ) . Because PTH has a short half-life of ϳ3 min, there is a rapid decrease in PTH after resection of an abnormal parathyroid gland. A drop of PTH concentrations by 50% after resection is interpreted as removal of the affected gland. In practice, this procedure generally is not needed by experienced surgeons for first time operations when anatomical landmarks are intact, but the procedure can be quite helpful for reoperations and unusual cases.
Support Systems for Laboratory Test Requests
Medical information systems should help promote quality healthcare. A basic premise of medicine is that the profession wants to provide quality service. Therefore, if there is agreement on a reasonable testing approach and if there is an efficient system available for implementing this approach, most medical professionals are likely to use this system. On the other hand, if there is not agreement on the approach or if the systems for implementing this approach are awkward and inefficient (or both), then it will be difficult to change medical practice. Therefore, it is prudent for laboratories to engage in dynamic interchange with clinicians and other healthcare professionals to help develop best practice paradigms for the use of laboratory tests (35 ) . It also is important for laboratorians to be involved in the design and implementation of support systems to help improve medical practice. For example, electronic order entry systems could be structured to provide structured test requests potentially following the strategies outlined here (after incorporating modifications to adjust to the preferences of the local practice). Test orders could be packaged according to the signs and symptoms of patient presentations, such as those that are characteristic of suspected Cushing syndrome or pheochromocytoma. When available, electronic medical records could be searched for appropriate clinical signs and symptoms or medications that might interfere. When this information is not available, queries could be made (in real time) to the healthcare provider for key data. When appropriate signs and symptoms do not match the defined criteria and when interfering medications are identified, real-time advisories could be provided.
The structured laboratory request forms could include automatic laboratory test cascades in which follow-up tests are performed when the initial tests and clinical information meet certain prescribed criteria. For example, follow-up free thyroxine, triiodothyronine, and anti-thyroperoxidase antibody measurements could be triggered by abnormal thyrotropin tests results (36 ) . These structured orders also should assure that key paired hormone measurements are performed concurrently when that information is needed to interpret test results efficiently.
Quality Performance Specifications
Effective healthcare strategies are critically dependent on reliable laboratory measurements. The laboratory test strategies outlined above could be viewed as being similar to public health policies that are optimized for the care of a large population of cases defined by certain common characteristics (such as recommendations for pneumonia vaccine for patients Ն65 years of age) (37 ) . Specific decision limits for these policies are chosen to optimize sensitivity and specificity. Similarly, specific decision limits should be defined for the laboratory test strategies that will optimize the aggregate performance.
The current heterogeneity of laboratory test methodologies, combined with the changes in test values over time as a result of calibration and reagent lot differences, makes the optimization and generalization of test strategies difficult. Consider the hypothetical laboratory test depicted in Fig. 4 , with a gaussian distribution of test values. If this test is used as a frontline test for identifying patients at risk for a specific disease and the decision threshold for follow-up testing is set at ϩ2 SD, then 2.3% of the patients tested would be positive on screening. On the other hand, if the laboratory test measurements were "shifted" upward 1 SD, then 15.8% would be positive on screening. In terms of healthcare policy, this represents an almost 700% increase in the number of patients subjected to additional medical investigation. This potential increase in expense should more than offset the cost of providing laboratory testing with tighter analytical performance specifications. This hypothetical gaussian model is not very different from many laboratory test systems. Consider serum calcium measurements. When used in a general case-finding mode in an ambulatory patient population, ϳ19 cases per 1000 would have an increased calcium concentration at The performance limits currently maintained by most laboratories are much wider than the limits required to optimally control the downstream effects of laboratorybased test strategies. For example, the CLIA '88 performance limits are Ϯ 10 mg/L (Ϯ 1 mg/dL) for calcium, Ϯ 25% for cortisol measurements, and Ϯ 20% for thyroxine measurements. The limits set by most equipment and reagent systems also are quite wide for endocrine tests. If tests are allowed to vary within these performance limits, the number of patient values crossing key decision thresholds could show extremely wide fluctuations. For example, almost all calcium measurements would be abnormal with a 10 mg/L (1.0 mg/dL) upward shift. Tolerance limits need to be much tighter to ensure more uniform practice over time (38, 39 ) .
A second laboratory performance issue for many endocrine tests is the lack of uniformity across manufacturers. Currently, there is little incentive for manufacturers to provide uniform test values. Actually, there may be an incentive for manufacturers to provide unique values because that makes it more difficult for laboratories to change test methods. This variation across methods makes the implementation of laboratory-based guidelines difficult because each guideline must have method-dependent decision limits. This heterogeneity of test values also makes it difficult for clinicians to work in an integrated health system using multiple test methods. A major incentive for reagent manufacturers to provide uniform test values would be a requirement for absolute vs peer group grading criteria for proficiency tests. However, a difficult issue with that concept is the establishment of the "true" target values for the proficiency test specimens (40 ) .
Interpretive Reporting
An important part of the implementation of decisionfocused test strategies is the interpretation of the test results. Most endocrine test strategies require integration of multiple laboratory and clinical data elements. It would be logical to include these multiple data elements in an integrated test report along with reference data for the appropriate decision categories. Unfortunately, most laboratory information systems are single-test oriented. In addition, most systems do not provide graphics; therefore, it is difficult to aggregate test information from multiple reference populations, especially test data involving more than one variable.
A plot of reference data for concurrent measurements of calcium and PTH concentrations is shown in Fig. 5 (41 ) . Display of this form of reference data should help the clinician interpret these test variables better than using single variable reference limits. Fig. 5 helps to illustrate the concept of inappropriately increased PTH values in patients with hypercalcemia, although these PTH values would not be flagged as abnormal by computer systems that only consider tests univariately.
Programs have been developed for automated computer diagnosis based on laboratory data. Most of these programs are not used in patient care because the reporting objective generally is not to provide a diagnosis, which should involve the full expertise of the healthcare provider, but rather to display information that can be integrated efficiently with other patient information available to the clinician to help them make optimal decisions. Most clinicians are skeptical of diagnostic systems that do not openly display the diagnostic criteria because they cannot be assured that their patients match the assumptions used by these systems. These issues of open information display may become more problematic as laboratory tests become more complex and proprietary support systems are developed.
Outcomes Monitoring
Many endocrine test systems are well suited for outcome monitoring (42 ) . Test strategies can be tracked in terms of sensitivity and specificity. Short-term tracking may overestimate sensitivity because missed cases may not be identified. However, surgically confirmed cases of endocrine tumors generally could be tracked, especially in an integrated healthcare system. For example, pituitary, adrenal, gonadal, and parathyroid tumors could be compared to their key laboratory tests to track strategy sensitivity. The monitoring of test specificity generally should be more complete, especially if patients identified as positive on screening are appropriately followed up with confirmatory tests. Other factors that could be tracked include the incidence of test interference and the number of requests for extra tests.
A major problem with outcome monitoring of laboratory tests is that many patients do not present with only one-symptom complexes. Therefore, a series of test strategies may be needed to resolve patients' problems. The test strategies should be targeted at presentation syndromes rather than at final diagnoses. It is much easier to define appropriate test sequences retrospectively once the diagnosis is known than it is to prospectively evaluate patients with complex signs and symptoms. Therefore, clinicians must be careful in deciding which tests are inappropriate or extra. On the other hand, there are considerable opportunities for improving healthcare strategies, and probably many of the tests currently performed are not necessary.
Summary
In anticipation of closer scrutiny of laboratory practice, it is prudent that laboratorians and clinicians work together closely to ensure that tests are used for optimal care. The key issues for each disease presentation must be well defined to determine the best laboratory test strategies. Twenty-four-hour urine specimens (with complete collection) offer advantages of integrating our pulsatile secretion spikes and diurnal variations and, therefore, are better than plasma tests for several endocrine disorders. On the other hand, plasma samples are valuable for evaluating timed response and for evaluating patients with impaired renal function. Concurrent, paired measurements of stimulatory and target analytes are essential for classifying abnormalities of endocrine systems controlled by negative feedback. The specificity of modern immunoassays and chromatography systems minimizes the need for some of the early nonspecific tests or certain provocative endocrine tests.
Standardized healthcare delivery systems can help minimize undesirable variations in practice. If consensus can be achieved for selected test strategies in a given medical practice, laboratorians can help build delivery systems that should improve the likelihood of best practice occurring. Mechanisms for these delivery systems may include decision support information to facilitate test orders and reports that integrate test values with other clinical information. Decision-focused test strategies also can help define the analytic performance standards needed for optimal laboratory support of patient care.
